Safety, tolerability, and efficacy of orally administered cannabinoids in MS
- 14 May 2002
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Neurology
- Vol. 58 (9) , 1404-1407
- https://doi.org/10.1212/wnl.58.9.1404
Abstract
The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to investigate safety, tolerability, and efficacy of oral Delta(9)-Tetrahydrocannabinol (THC) and Cannabis sativa plant extract. Both drugs were safe, but adverse events were more common with plant-extract treatment. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant's global impression.Keywords
This publication has 5 references indexed in Scilit:
- Endocannabinoids and multiple sclerosis: a blessing from the ‘inner bliss’?Trends in Pharmacological Sciences, 2000
- Cannabinoids control spasticity and tremor in a multiple sclerosis modelNature, 2000
- Recommendations from the national multiple sclerosis society clinical outcomes assessment task forceAnnals of Neurology, 1997
- Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteersClinical Pharmacology & Therapeutics, 1994
- Measuring Functioning and Well-Being: The Medical Outcomes Study ApproachPublished by Rand Corporation ,1992